Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
heart attack
Biotech
CeleCor's emergency heart attack med wins in key phase 3 trial
CeleCor presented the results of its pivotal CeleBrate phase 3 trial at the the American Heart Association’s annual scientific sessions.
Zoey Becker
Nov 11, 2025 4:45am
Neurescue nets European approval in non-shockable cardiac arrest
Sep 12, 2025 2:00pm
J&J delivers 10-year Impella gains in severe heart attacks
Sep 2, 2025 1:30pm
Ablation before meds shows gains in v-tach after heart attack
Nov 18, 2024 11:45am
J&J's Abiomed pump reduces deaths after widowmaker heart attacks
Apr 8, 2024 12:12pm
Idorsia bags $350M upfront from Viatris for 2 late-phase assets
Feb 28, 2024 7:56am
